CVS Health Makes Headway in Stabilizing Aetna: What's Driving It?

CVS Health is actively stabilizing its Aetna insurance arm, which previously struggled with elevated utilization and weak Medicare Advantage ratings, through strategic initiatives including streamlining prior authorizations, launching clinical collaboration programs, and optimizing product mix. Aetna will also exit states with independently run ACA plans by 2026, having identified a $431 million premium deficiency related to this. Despite past headwinds, CVS expresses bullishness on Aetna's turnaround, a sentiment reflected in its year-to-date stock surge of 64.8%, significantly outperforming the industry, and its valuation at a forward five-year earnings multiple of 10.72, below the industry average.

Analysis

CVS Health is executing a multifaceted turnaround for its Aetna insurance division, addressing prior headwinds from elevated post-pandemic utilization, Medicaid redeterminations, and unfavorable Medicare Advantage ratings. The stabilization strategy involves concrete operational enhancements, such as bundling prior authorizations for cancer treatments and launching a clinical collaboration program with hospitals to reduce readmissions. These initiatives are supported by positive forward-looking developments, including strong Medicare star ratings for the 2025 payment year and successful Medicaid rate advocacy. Management is also demonstrating strategic discipline by exiting independently-run ACA insurance markets by 2026, a decision underscored by a determined $431 million premium deficiency for the 2025 coverage year. This operational progress has fueled a 64.8% year-to-date surge in CVS shares, starkly outperforming the industry's 2.1% decline. Despite this rally, the stock trades at a forward five-year earnings multiple of 10.72, a discount to the industry average of 15.03, and is supported by a bullish trend in 2025 consensus earnings estimates. However, broader sector challenges persist, as evidenced by competitor UnitedHealth Group's medical care ratio increasing 430 basis points, highlighting the critical importance of Aetna's cost-control initiatives.

Key Decisions for Investors

• Given the stock's 64.8% year-to-date gain and a valuation multiple of 10.72 that remains below the industry average, investors may find the stock attractive if they believe the Aetna turnaround can be sustained.
• The strategic decision to exit certain ACA markets by 2026, despite a near-term $431 million premium deficiency, should be viewed as a positive long-term de-risking measure aimed at improving profitability.
• Investors should monitor Aetna's ability to manage medical cost trends through its new operational programs, as this is critical for success amid the industry-wide pressures highlighted by rising medical care ratios at peers.
• The 'Hold' rating from Zacks suggests that after a significant price appreciation, it may be prudent to await further data confirming sustained margin improvement in the insurance segment before significantly increasing exposure.